Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study-Reference-Cited by-同舟云学术

Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study

Published:2022-09-22 Issue:1 Volume:108 Page:267-272
ISSN:1592-8721
Container-title:Haematologica
language:
Short-container-title:haematol

Author:

Launspach Michael,Temel Dennis,Ohlendorf Emily,Zirngibl Felix,Materne Bianca,Oevermann Lena,Deubzer Hedwig E.,Henssen Anton G.,Künkele Annette,Hundsdörfer Patrick,Bernuth Horst von,Pruß Axel,Eggert Angelika,Stackelberg Arend von,Lang Peter,Schulte Johannes H.

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Reference15 articles.

1. Glass B, Hasenkamp J, Wulf G. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol. 2014; 5(7):757-766.

2. Salles G, Barrett M, Foà R. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017; 34(10):2232-2273.

3. Berghen N, Vulsteke JB, Westhovens R, Lenaerts J, De Langhe E. Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. Acta Clin Belg. 2019; 4(4):272-279.

4. Ottaviano G, Marinoni M, Graziani S. Rituximab unveils hypogammaglobulinemia and immunodeficiency in children with autoimmune cytopenia. J Allergy Clin Immunol Pract. 2020; 8(1):273-282.

5. Choquet S, Leblond V, Herbrecht R. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006; 107(8):3053-3057.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Clinical Outcomes and B Cell Immune Reconstitution Following Allo-HCT With Prophylactic, Post-Transplant Rituximab;Transplantation and Cellular Therapy;2024-05

2. Applying Rituximab During the Conditioning Regimen Prevents Epstein–Barr Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplant in a Children’s Cohort: A Retrospective Case–Control Study;Infectious Diseases and Therapy;2023-07-20

3. The Development of New Agents for Post-Hematopoietic Stem Cell Transplantation Non-Infectious Complications in Children;Journal of Clinical Medicine;2023-03-09